{
    "guideline_id": "2024CSCO原发性肝癌.txt",
    "cancer_info": {
        "cancer_name": "Hepatocellular Carcinoma"
    },
    "clinical_recommendations": [
        {
            "clinical_context": "High-risk population screening",
            "recommendation_type": "Diagnostic Strategy",
            "recommendation_content": "每6个月腹部超声+血清AFP检测；阳性时补充腹部动态增强CT/MRI（如AFP≥400ng/ml或动态升高）",
            "treatment_line": "",
            "biomarker_requirements": [
                {
                    "biomarker_name": "AFP",
                    "status": "",
                    "testing_guidance": "Serum testing"
                }
            ],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Suspected HCC diagnosis",
            "recommendation_type": "Diagnostic Strategy",
            "recommendation_content": "肝穿刺活检为首选（18G空芯针），采用七点基线法取材；镜下评估Edmondson-Steiner分级和微血管侵犯（MVI）分级",
            "treatment_line": "",
            "biomarker_requirements": [
                {
                    "biomarker_name": "HepPar1",
                    "status": "",
                    "testing_guidance": "Immunohistochemistry for diagnosis"
                },
                {
                    "biomarker_name": "GPC3",
                    "status": "",
                    "testing_guidance": "Immunohistochemistry for diagnosis"
                },
                {
                    "biomarker_name": "Arg1",
                    "status": "",
                    "testing_guidance": "Immunohistochemistry for diagnosis"
                }
            ],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Clinical diagnosis based on imaging",
            "recommendation_type": "Diagnostic Strategy",
            "recommendation_content": "动态增强CT/MRI确诊标准：肿瘤≤1cm需1种典型表现（动脉期强化+静脉期洗脱）；1-2cm需≥2种典型表现；>2cm需1种典型表现+AFP异常",
            "treatment_line": "",
            "biomarker_requirements": [
                {
                    "biomarker_name": "AFP",
                    "status": "",
                    "testing_guidance": "Serum testing for diagnosis"
                }
            ],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Ia/Ib/IIa期",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "首选手术切除",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level IA",
            "evidence_level": "Evidence IA"
        },
        {
            "clinical_context": "IIb/IIIa期 (resectable)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "手术切除 + 辅助治疗（TACE或免疫治疗）",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level IIA",
            "evidence_level": "Evidence IIA"
        },
        {
            "clinical_context": "IIb/IIIa期 (potentially resectable)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "新辅助治疗（靶向免疫联合或放疗）降期后手术",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level IIB",
            "evidence_level": "Evidence IIB"
        },
        {
            "clinical_context": "Post-operative with high-risk factors (MVI positive, margin positive, AFP>400ng/ml)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "TACE or 阿替利珠单抗+贝伐珠单抗辅助治疗",
            "treatment_line": "Adjuvant",
            "biomarker_requirements": [
                {
                    "biomarker_name": "AFP",
                    "status": ">400ng/ml",
                    "testing_guidance": "Serum testing for risk stratification"
                }
            ],
            "recommendation_level": "Level IA",
            "evidence_level": "Evidence IA"
        },
        {
            "clinical_context": "Ia期 or Ib期 (tumor ≤3cm or ≤3 nodules all ≤3cm)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "消融治疗（射频RFA或微波MWA优于冷冻/无水乙醇）",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level IA",
            "evidence_level": "Evidence IA"
        },
        {
            "clinical_context": "IIb期",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "TACE",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level IA",
            "evidence_level": "Evidence IA"
        },
        {
            "clinical_context": "IIIa期",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "TACE + 贝伐珠单抗 + 度伐利尤单抗",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level IA",
            "evidence_level": "Evidence IA"
        },
        {
            "clinical_context": "IIIb期",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "HAIC（奥沙利铂方案）+ 靶向免疫联合",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level IIB",
            "evidence_level": "Evidence IIB"
        },
        {
            "clinical_context": "Early-stage HCC not suitable for surgery",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "根治性放疗（SBRT）",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level IIB",
            "evidence_level": "Evidence IIB"
        },
        {
            "clinical_context": "Palliative care for portal vein tumor thrombus, bone metastasis, or lymph node metastasis",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "姑息性放疗 for symptom relief",
            "treatment_line": "Palliative",
            "biomarker_requirements": [],
            "recommendation_level": "Level IIA",
            "evidence_level": "Evidence IIA"
        },
        {
            "clinical_context": "Advanced HCC (Child-Pugh A/B级)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "一线治疗：阿替利珠单抗+贝伐珠单抗（T+A）",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level IA",
            "evidence_level": "Evidence IA"
        },
        {
            "clinical_context": "Advanced HCC (Child-Pugh A/B级)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "一线治疗：信迪利珠单抗+贝伐珠单抗",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level IA",
            "evidence_level": "Evidence IA"
        },
        {
            "clinical_context": "Advanced HCC (Child-Pugh A/B级)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "一线治疗：多纳非尼 or 仑伐替尼（靶向单药）",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level IA",
            "evidence_level": "Evidence IA"
        },
        {
            "clinical_context": "Advanced HCC (Child-Pugh A/B级)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "一线治疗：FOLFOX4化疗（奥沙利铂+氟尿嘧啶）",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level IA",
            "evidence_level": "Evidence IA"
        },
        {
            "clinical_context": "Advanced HCC after first-line progression",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "二线治疗：瑞戈非尼（for sorafenib resistance）",
            "treatment_line": "Second-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level IA",
            "evidence_level": "Evidence IA"
        },
        {
            "clinical_context": "Advanced HCC after first-line progression",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "二线治疗：雷莫西尤单抗（for AFP≥400ng/ml）",
            "treatment_line": "Second-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "AFP",
                    "status": "≥400ng/ml",
                    "testing_guidance": "Serum testing for eligibility"
                }
            ],
            "recommendation_level": "Level IA",
            "evidence_level": "Evidence IA"
        },
        {
            "clinical_context": "Advanced HCC after first-line progression",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "二线治疗：帕博利珠单抗（unlimited by AFP）",
            "treatment_line": "Second-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level IA",
            "evidence_level": "Evidence IA"
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "用于风险预测（如aMAP评分）、诊断确认（如AFP、PIVKA-II）、预后评估（如MVI分级、AFP>400ng/ml）、指导靶向治疗（如VEGFR、RAS、MET变异），并预测免疫治疗响应（如PD-L1、TMB、MSI/MMR状态）。特殊亚型如纤维板层型HCC由DNAJB1-PRKACA融合基因指导诊断（FISH检测）。"
    },
    "tcm_recommendations": [
        {
            "syndrome_type": "",
            "tcm_treatment_plan": "淫羊藿素软胶囊（阿可拉定）用于特定生物标志物富集人群",
            "recommendation_grade": "Level IB"
        },
        {
            "syndrome_type": "",
            "tcm_treatment_plan": "榄香烯注射液/口服液用于保肝和减轻癌痛",
            "recommendation_grade": "Level IIA"
        },
        {
            "syndrome_type": "",
            "tcm_treatment_plan": "消癌平注射液/片剂用于抑制肿瘤进展",
            "recommendation_grade": "Level IIA"
        },
        {
            "syndrome_type": "",
            "tcm_treatment_plan": "槐耳颗粒用于术后防复发",
            "recommendation_grade": "Level IIA"
        },
        {
            "syndrome_type": "",
            "tcm_treatment_plan": "辨证论治配合西医治疗，减轻毒性（如放疗/化疗后肝损伤）",
            "recommendation_grade": "Level IIA"
        },
        {
            "syndrome_type": "",
            "tcm_treatment_plan": "辨证论治用于晚期姑息，缓解腹水、黄疸、癌痛",
            "recommendation_grade": "Level IIA"
        }
    ]
}